Headache, Migraine
Conditions
Brief summary
This is a prospective open-label randomized study assessing similar endpoints included in the pivotal trial for ubrogepant, which are pain freedom and freedom from the most bothersome symptom at two hours. Patients between 18-75 years old with a one-year history of migraine who experience ≥3 migraine days/month will be screened. This study will include migraine patients treated with or without injectable CGRPmAbs. As was the case in the clinical trials, this will be a single-attack study. Patients will be randomized to treat a single migraine attack with ubrogepant 50mg or 100mg. Patients will record dosing time, most bothersome symptom (nausea, photophobia, or phonophobia - chosen by patient), pain freedom, pain relief, the use of a 2nd dose if required, and adverse reactions. Patients will follow up within 30 days post treatment. Patients will be assessed for adverse events, and the safety data will be compared with the original clinical trial.
Detailed description
The purpose of this study is to examine the safety and efficacy of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality). There are currently very limited data available about the use of CGRP receptor antagonists in this population, resulting in difficulty obtaining prior authorization to use ubrogepant in patients currently treated with CGRPmAbs. Questions remain as to whether these patients, whose CGRP or CGRP receptors are suppressed, will experience the same safety and efficacy results as patients without such suppression by CGRPmAbs. This is a prospective open-label randomized study assessing similar endpoints included in the pivotal trial for ubrogepant, which are pain freedom and freedom from the most bothersome symptom at two hours. Patients between 18-75 years old with a one-year history of migraine who experience ≥3 migraine days/month will be screened. This study will include migraine patients treated with or without injectable CGRPmAbs. As was the case in the clinical trials, this will be a single-attack study. Patients will be randomized to treat a single migraine attack with ubrogepant 50mg or 100mg. Patients will record dosing time, most bothersome symptom (nausea, photophobia, or phonophobia - chosen by patient), pain freedom, pain relief, the use of a 2nd dose if required, and adverse reactions. Patients will follow up within 30 days post treatment. Patients will be assessed for adverse events, and the safety data will be compared with the original clinical trial. Primary Objective: To evaluate the safety and efficacy of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality). Primary Endpoint: * Pain freedom at 2 hours. * Freedom from most bothersome symptom at 2 hours Secondary Objectives: To assess improvements with the addition of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality). Secondary Endpoint: * Pain relief at 2 hours (this is different from pain freedom: moderate to severe pain reduced to mild or no pain) * Percentage of patients with sustained pain relief from 2-24 hours after initial dose * Percentage of patients with sustained pain freedom from 2-24 hours after initial dose * Pain relief at 2 hours after 2nd dose * Percentage of patients with sustained pain relief from 2-24 hours after 2nd dose * Percentage of patients with sustained pain freedom from 2-24 hours after 2nd dose
Interventions
DRUGUbrogepant 50 MG [Ubrelvy]
Ubrogepant 50 MG \[Ubrelvy\]
DRUGUbrogepant 100 MG [Ubrelvy]
Ubrogepant 100 MG \[Ubrelvy\]
Sponsors
AbbVie
Chicago Headache Center & Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Phase IV prospective open label randomized clinical study evaluating safety and efficacy of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality).
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male or female patients ages 18 to 75 years, at screening (Visit 1). * At least a 1-year history of migraine with or without aura. * History of ≥3 monthly headache days of at least moderate severity. * Study patient currently on CGRPmAbs must be on treatment \> 1 month at screening. * By history, the patient's migraines typically last between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom
Exclusion criteria
* History of \<3 monthly headache days of at least moderate severity * Concomitant use of strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. John's Wort) * Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) * Currently on Botox treatment for CM. * Concomitant use of gepants as a preventative treatment. * Current user of illicit drugs, or a history within 1 year prior to screening (visit 1) of drug or alcohol abuse or dependence * Clinically significant hematologic, endocrine, cardiovascular, pulmonary, gastrointestinal, or neurologic disease. If there is a history of such a disease, but the condition has been stable for more than 1 year prior to screening (visit 1) and is judged by the PI as not likely to interfere with participation in the study, the participant may be included. * Woman is pregnant, planning to become pregnant during the course of the study, or currently lactating.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain freedom | 2 hours post treatment | Pain freedom at 2 hours. |
| Freedom from most bothersome symptom | 2 hours post treatment | Freedom from most bothersome symptom at 2 hours. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients with sustained pain freedom from 2-24 hours after initial dose. | 2-24 hours after initial dose | Percentage of patients with sustained pain freedom from 2-24 hours after initial dose. |
| Pain relief at 2 hours after 2nd dose | 2 hours after 2nd dose | Pain relief at 2 hours after 2nd dose. |
| Pain relief at 2 hours | 2 hours post treatment | Pain relief at 2 hours (this is different from pain freedom: moderate to severe pain reduced to mild or no pain). |
| Percentage of patients with sustained pain freedom from 2-24 hours after 2nd dose. | 2-24 hours after 2nd dose | Percentage of patients with sustained pain freedom from 2-24 hours after 2nd dose. |
| Percentage of patients with sustained pain relief from 2-24 hours after 2nd dose. | 2-24 hours after 2nd dose | Percentage of patients with sustained pain relief from 2-24 hours after 2nd dose. |
| Percentage of patients with sustained pain relief from 2-24 hours after initial dose. | 2-24 hours after initial dose | Percentage of patients with sustained pain relief from 2-24 hours after initial dose. |
Countries
United States
Outcome results
None listed